BEAM
Held · Bookmarked
0 · 0
portfolios · users
Platform exposure
—
13F filers
1
institution
Market cap
$3.5B
103M shares
52-week range
$15.60 – $36.88
94% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.31%
Easy to borrow
Price (6 mo)
Beam Therapeutics Inc. Common Stock
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
www.beamtx.com- Employees
- 522
- IPO / List date
- Feb 6, 2020
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds BEAM.
Super investors & insiders
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 12,107 | $236.5K |
- Form 4 filed Jun 22, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Jun 5, 2026↗
- Form 4 filed Apr 6, 2026↗
- Form 4 filed Apr 6, 2026↗
- Form 4 filed Apr 6, 2026↗
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Recent trades on TradeandTell
No one on the platform has traded BEAM yet.
$BEAM chatter on StockTwits
Genomics is starting to look like it’s getting pulled into the broader AI re-rating conversation. $ARKG is trying to push out of a long Stage 1 base - not explosive yet, but the structure is clearly tightening and starting to shift. The idea here is pretty straightforward: if AI tools actually start compressing timelines in drug discovery and biotech workflows, this sector doesn’t re-rate slowly. It tends to move in chunks when sentiment flips. Names I’m watching: $TEM - AI + healthcare infrastructure angle $TWST - synthetic biology platform with heavy data leverage $BEAM - gene editing with longer-duration innovation cycles Still early days, but this is one of those areas where narrative and real productivity gains could start reinforcing each other. Worth keeping on radar.
View on StockTwits ↗
Genomics / AI-driven biotech is starting to look like one of the next major rotation themes the market is quietly pricing in. $ARKG - pushing out of a long consolidation base, early signs of a potential regime shift in biotech risk appetite What’s interesting here is not just the ETF move - it’s the underlying stock-level strength beginning to emerge beneath it. Key names I’m watching closely in this rotation: $TEM - data-driven healthcare + AI diagnostics, narrative shifting from “early stage” to “scaling execution” $TWST - synthetic biology platform with real industrial + pharma data demand tailwinds $BEAM - precision gene editing exposure tied to next-gen therapeutic pipelines This is how early sector rotation usually looks - ETF breaks first, then selective leaders start to separate. If this continues, genomics could be transitioning from a “speculative AI adjacency” to a true standalone leadership theme. Worth watching closely while it’s still early.
View on StockTwits ↗
Genomics set out to be one of the biggest winners from AI? The markets are certainly starting to think so... $ARKG breaking out of a massive stage 1 base Could see a rerate in this sector very quickly.. My favorite stocks: $TEM $TWST $BEAM Watch this sector closely, as it starts to ignite.
View on StockTwits ↗
Beam Therapeutics' $BEAM weekly moving average support cluster ascends quietly and pushes the stock to challenge its resistance band (225/237-week EMAs) for the 7th time now since January 2026. Watching the price action at this spot. -- 📉BEST Respected MA S&R Lines📈
View on StockTwits ↗
$WVE SELLING panic is losing steam. MACD triggered a buy signal on June 9th and RSI is officially out of extreme oversold territory. In derivatives, volume is heavily skewed toward bullish calls. Solid support at $5.00 - $5.40, with resistance sitting at $6.20 - $6.50. Catalysts coming soon. Today our competitor $BEAM got FDA clearance... We are next!
View on StockTwits ↗
$NTLA $CRBU $PRME $BEAM $REGN lol follow the Noble prize winners … Good job Jenny
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.